BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Porcelli T, Sessa F, Luongo C, Salvatore D. Local ablative therapy of oligoprogressive TKI-treated thyroid cancer. J Endocrinol Invest 2019;42:871-9. [DOI: 10.1007/s40618-019-1001-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Porcelli T, Sessa F, Gambale C, Luongo C, Salvatore D. Management of one patient with oligoprogressive thyroid cancer during treatment with lenvatinib. Future Oncol 2019;15:21-5. [PMID: 31411063 DOI: 10.2217/fon-2019-0110] [Reference Citation Analysis]
2 Alomran R, White M, Bruce M, Bressel M, Roache S, Karroum L, Hanna GG, Siva S, Goel S, David S. Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR). BMC Cancer 2021;21:303. [PMID: 33757458 DOI: 10.1186/s12885-021-08042-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Porcelli T, Luongo C, Sessa F, Klain M, Masone S, Troncone G, Bellevicine C, Schlumberger M, Salvatore D. Long-term management of lenvatinib-treated thyroid cancer patients: a real-life experience at a single institution. Endocrine 2021;73:358-66. [PMID: 33537956 DOI: 10.1007/s12020-021-02634-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Hu J, Xing K, Zhang Y, Liu M, Wang Z. Global research Trends in Tyrosine Kinase Inhibitors: A Co-Word and Visualized Study (Preprint). JMIR Medical Informatics. [DOI: 10.2196/34548] [Reference Citation Analysis]